Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study

Wang, Liming; Wiener, Jeffrey; Bulterys, Marc; Wei, Xiaoyu; Chen, Lili; Liang, Shujia; Shepard, Colin W.; Wang, Lınhong; Wang, Ailing; Zhang, Fujie; Kourtis, Athena P.

doi:10.1093/infdis/jiw439

Cited by 14 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nine included studies, which involved 607 patients, reported the undetectable rates of HBV DNA [ 12 – 14 , 16 – 18 , 20 – 22 ]. Because there was significant heterogeneity among these studies ( P = 0.008, I 2 = 61%), the random-effect method was applied to calculate the overall effects.…”

Section: Resultsmentioning

confidence: 99%

“…In this meta-analysis, we evaluated the between-study heterogeneity by using four different methods, including the chi-square-based Q statistical test (Cochran’s Q statistic) [ 32 ] to test for heterogeneity, the I 2 statistic to quantify the heterogeneity [ 33 ], Galbraith plots to identify outliers as the possible major sources of heterogeneity [ 34 ], and a sensitivity analysis to test the effect of each study on the heterogeneity. The result showed that the heterogeneity of the present study was primarily derived from these two studies (Jain2006 and Wang2016) [ 12 , 14 ]. The biggest differences between these two studies and others are the patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Luo

Jiang

Ren

2018

Virol J

View full text Add to dashboard Cite

BackgroundCurrently, there is no consensus on the efficacy and safety of lamivudine (LAM) plus tenofovir disoproxil fumarate (TDF) combination therapy versus lamivudine monotherapy in HBV/HIV coinfected patients.MethodsA comprehensive literature search was performed in English and Chinese databases. Both relevant dichotomous and continuous variables were extracted, and the combined outcomes were expressed as a risk ratio (RR) or a standard mean difference (SMD).ResultsEleven eligible studies were included in our analysis. For HBV-relevant outcomes, the proportion of patients with undetectable HBV, the rates of serum alanine aminotransferase (ALT) normalization and hepatitis B e antigen (HBeAg) loss were higher in the combination therapy group than the monotherapy group (RR = 1.42, 95% CI: 1.14–1.76, P = 0.002; RR = 1.36, 95% CI: 1.17–1.58, P < 0.0001; RR = 2.74, 95% CI: 1.20–6.22, P = 0.02). In addition, the rate of HIV RNA-negative conversion was higher in the combination therapy group than the monotherapy group (RR = 1.26, 95% CI: 1.11–1.42, P = 0.0003).ConclusionLAM plus TDF combination therapy was more efficacious than LAM monotherapy in HBV/HIV coinfected patients. As time passes, this difference becomes more pronounced.Electronic supplementary materialThe online version of this article (10.1186/s12985-018-1050-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Luo

Jiang

Ren

2018

Virol J

View full text Add to dashboard Cite

show abstract

“…The main limitation of the RCTs was the lack of blinding in the PROMISE trial 12 and two smaller RCTs. 34 38 The PROMISE trial was also stopped early, but that decision was based on the reduction in vertical transmission of cART compared with AZT monotherapy and therefore should not bias comparison of tenofovir-based cART versus alternative NRTI-based cART, the focus of this review. 12 The PROMISE trial randomised 823 women, most in Africa, to the comparison of interest.…”

Section: Resultsmentioning

confidence: 99%

“…Two observational studies including 1850 patients 12 39 and two small RCTs with 75 patients 34 35 reported vertical transmission of HIV. The PROMISE trial did not report vertical transmission in the groups as randomised, and therefore we considered it an observational study for this outcome 12 ; there were no other transmission events in any of the other studies.…”

Section: Resultsmentioning

confidence: 99%

Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo assess the impact of various antiretroviral/antiviral regimens in pregnant women living with HIV or hepatitis B virus (HBV).DesignWe performed random effects meta-analysis for HIV-related outcomes and network meta-analysis for HBV outcomes, and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess quality separately for each outcome.Data sourcesEmbase and Medline to February 2017.Eligibility criteriaFor maternal outcomes, we considered randomised controlled trials (RCTs) comparing tenofovir-based regimens with those with alternative nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). For child outcomes, we included RCTs and comparative observational studies of tenofovir-based regimens versus alternative NRTIs regimens or, for HBV, placebo.ResultsTen studies (seven RCTs) met the inclusion criteria for maternal and child outcomes, and an additional 33 studies (12 RCTs) met the inclusion criteria for HBV-specific outcomes. The most common comparison was tenofovir and emtricitabine versus zidovudine and lamivudine. There was no apparent difference between tenofovir-based regimens and alternatives in maternal outcomes, including serious laboratory adverse events (low certainty) and serious clinical adverse events (moderate certainty). There was no difference between NRTIs in vertical transmission of HIV: 1 more per 1000, 8 fewer to 10 more, low certainty; or vertical transmission of HBV: 7 fewer per 1000, 10 fewer to 38 more, moderate certainty. We found moderate certainty evidence that tenofovir/emtricitabine increases the risk of stillbirths and early neonatal mortality (51 more per 1000, 11 more to 150 more) and the risk of early premature delivery at <34 weeks (42 more per 1000, 2 more to 127 more).ConclusionsTenofovir/emtricitabine is likely to increase stillbirth/early neonatal death and early premature delivery compared with zidovudine/lamivudine, but certainty is low when they are not coprescribed with lopinavir/ritonavir. Other outcomes are likely similar between antiretrovirals.PROSPERO registration numberCRD42017054392.

show abstract

“…WHO now recommends the use of tenofovir as part of fi rst-line treatment for HIV and for the treatment of chronic HBV infection, including among pregnant HIV-HBV-coinfected women. Hence, expansion of tenofovirbased treatment for HIV will provide effective treatment for HBV infection for those who are coinfected with HIV and HBV, and will help prevent transmission of HBV from mother to child (33). However, data are lacking on the actual coverage of tenofovir-based treatment for people who are coinfected with HIV and HBV.…”

Section: Prevalence Of Hbv-hiv Coinfectionmentioning

confidence: 99%

Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink

Ferreira¹,

Stuurman²,

Horsmans

et al. 2020

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Objective Assess the risk of progression to cirrhosis and hepatocellular carcinoma (HCC) due to hepatitis B virus (HBV)-infection in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods Retrospective cohort study in the UK Clinical Practice Research Datalink with three cohorts: subjects with T2DM and HBV infection (T2DM+HBV cohort; N = 297), with T2DM without HBV-infection (T2DM cohort; N = 261 865), and with HBV-infection without T2DM (HBV cohort; N = 3630). Primary analyses were performed on the three cohorts and secondary analyses on subcohorts including patients with NAFLD diagnosis code (N = 6599). Case/outcome definitions were formulated with International Classification of Diseases/Read codes/laboratory results and classified using validated algorithms. Adjusted incidence rate ratios (IRR) were estimated with a Poisson regression model. Results When comparing the T2DM+HBV and T2DM cohorts, adjusted IRRs were 14.06 (95% confidence interval: 4.47–44.19) for cirrhosis and 2.83 (1.06–7.55) for HCC. When comparing the T2DM+HBV and HBV cohorts, adjusted IRRs were 0.68 (0.21–2.27) for cirrhosis and 1.39 (0.46–4.20) for HCC. No cirrhosis cases were identified in T2DM+NAFLD+HBV patients; IRs were 16.92/10 000 person-years (12.97–21.69) and 85.24/10 000 person-years (10.32–307.91) in the T2DM+NAFLD and NAFLD+HBV cohorts. Conclusion HBV-infection increased significantly the risk for cirrhosis among T2DM patients, however, not beyond the expected incremental risk among infected non-T2DM subjects. Our approach to evaluate the role of T2DM/NAFLD and HBV-infection in liver disease progression could be applied to other settings with higher HBV prevalence.

show abstract

Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study

Abstract: NCT01125696.

Cited by 14 publications

References 13 publications

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis

Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink

Contact Info

Product

Resources

About